Time：2024-09-14
The U.S. Food and Drug Administration (FDA) has successfully completed its inspection of Chinese Peptide Company, a Medtide Inc. subsidiary, following a five-day on-site review conducted June 10-14, 2024, at the company's Hangzhou facility in Zhejiang Province.
Medtide Inc. recently received the official FDA inspection report confirming that Chinese Peptide Company passed the comprehensive review. The inspection validated that the company's manufacturing operations and quality management systems fully meet FDA's rigorous Good Manufacturing Practice (GMP) standards, marking a significant milestone in the company's international certification efforts.
"This achievement represents strong validation from a leading global regulatory authority and positions us well for continued international expansion," the company stated. "We remain committed to maintaining the highest quality standards and compliance protocols as we serve the global peptide market."
About Chinese Peptide Company
Chinese Peptide Company operates as a specialized Contract Research, Development, and Manufacturing Organization (CRDMO) focused on peptides and oligonucleotides. The company provides comprehensive services spanning early-stage discovery through commercial production, supporting clients throughout the entire development lifecycle.
